CytomX Therapeutics (CTMX) Other financing activities (2015 - 2026)

CytomX Therapeutics (CTMX) has 12 years of Other financing activities data on file, last reported at $5.9 million in Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to $5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 million (up 3931.03% YoY) and the FY2025 annual result came in at $811000.0, changed N/A from the prior year.
• Other financing activities grew to $5.9 million in Q1 2026, from $381000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $29.4 million in Q3 2023 to a low of -$458000.0 in Q3 2022.
• A 5-year average of $3.0 million and a median of $254500.0 in 2024 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities tumbled 540.38% — and 2023, when it surged 6508.73%.
• Tracing CTMX's Other financing activities over 5 years: stood at -$458000.0 in 2022, then surged by 6508.73% to $29.4 million in 2023, then sank by 101.46% to -$430000.0 in 2024, then soared by 188.6% to $381000.0 in 2025, then jumped by 1436.75% to $5.9 million in 2026.
• The last three Other financing activities figures came in at $5.9 million (Q1 2026), $381000.0 (Q4 2025), and $253000.0 (Q3 2025), per Business Quant data.